Novo Signs Up Another Oral Insulin Partner, Hedging Its Bets
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk places another oral insulin technology bet with Emisphere; expands partnership with Merrion beyond insulin.
You may also be interested in...
Looking For The New Lantus: Next-Gen Diabetes Hopefuls Defy Risks
The diabetes market presents competitive, commercial, and regulatory challenges, but its size and breadth spur emerging biotechs to develop an ever-wider range of treatments and technologies.
Novo Nordisk Looks Ahead After Tresiba Setback, Bets Against Biosimilars
The Danish pharma is focused on the latest formulation technology for insulin and GLP-1 and combinations thereof to sustain its diabetes market leader position. It’s not particularly worried about biosimilars, despite two of its top sellers coming off-patent in the next few years.
For Some, Oral Insulin’s Allure Persists Despite Hurdles
The recent release of preliminary Phase III results for Generex Biotechnology Corp.’s buccal spray Oral-lyn put the challenging, but alluring for a few dogged developers, oral insulin development space back in the spotlight momentarily.